We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals

285 hedge funds and large institutions have $6.42B invested in Rhythm Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 101 increasing their positions, 89 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

776% more call options, than puts

Call options by funds: $16.4M | Put options by funds: $1.87M

25% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 51

13% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 89

2% more funds holding

Funds holding: 279285 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

1.43% less ownership

Funds ownership: 109.17%107.74% (-1.4%)

18% less capital invested

Capital invested by funds: $7.8B → $6.42B (-$1.38B)

Holders
285
Holders Change
+6
Holders Change %
+2.15%
% of All Funds
3.51%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
64
Increased
101
Reduced
89
Closed
51
Calls
$16.4M
Puts
$1.87M
Net Calls
+$14.5M
Net Calls Change
+$1.06M
Name Holding Trade Value Shares
Change
Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$580M
BlackRock
2
BlackRock
New York
$542M -$5.85M -60,183 -1%
BBA
3
Baker Bros. Advisors
New York
$487M
Primecap Management
4
Primecap Management
California
$297M -$5.95M -61,160 -2%
VPM
5
Vanguard Portfolio Management
Pennsylvania
$264M +$296M +3,040,718 New
VCM
6
Vanguard Capital Management
Pennsylvania
$258M +$289M +2,967,825 New
PA
7
Perceptive Advisors
New York
$206M -$16.8M -172,596 -7%
State Street
8
State Street
Massachusetts
$198M +$7.12M +73,236 +3%
Goldman Sachs
9
Goldman Sachs
New York
$171M +$13.1M +134,566 +7%
Westfield Capital Management
10
Westfield Capital Management
Massachusetts
$168M +$64.4M +661,965 +52%
Fidelity Investments
11
Fidelity Investments
Massachusetts
$147M -$1.62M -16,646 -1%
T. Rowe Price Associates
12
T. Rowe Price Associates
Maryland
$144M +$9.14M +94,029 +6%
PCH
13
Polar Capital Holdings
United Kingdom
$141M +$41.8M +430,194 +36%
Citadel Advisors
14
Citadel Advisors
Florida
$123M +$123M +1,265,297 +825%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$123M +$3.94M +40,540 +3%
JP Morgan Chase
16
JP Morgan Chase
New York
$120M +$12.6M +129,655 +9%
Federated Hermes
17
Federated Hermes
Pennsylvania
$112M -$32.8M -337,538 -21%
CC
18
Checkpoint Capital
California
$107M +$22.9M +235,000 +24%
AllianceBernstein
19
AllianceBernstein
Tennessee
$97.5M -$1.93M -19,820 -2%
Capital Research Global Investors
20
Capital Research Global Investors
California
$97M +$12.7M +130,374 +13%
Janus Henderson Group
21
Janus Henderson Group
United Kingdom
$79.9M -$20.2M -207,972 -18%
Point72 Asset Management
22
Point72 Asset Management
Connecticut
$73.6M +$40.6M +417,381 +97%
WP
23
Woodline Partners
California
$66M +$6.82M +70,112 +10%
Adage Capital Partners
24
Adage Capital Partners
Massachusetts
$63.1M +$10.1M +104,159 +17%
SL
25
Siren LLC
Connecticut
$63.1M +$21.9M +225,536 +45%

RYTM Hedge Fund Activity: Q1 2026 in Review

285 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2026, worth a combined $6.42B — down 18% from $7.8B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new RYTM positions and 51 closed out — a net gain of 13 holders — while 101 added to existing stakes and 89 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $123M. The largest seller was NEA Management Company, exiting entirely with an estimated $311M sold.

  • 285 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2026, up from 279 in Q4 2025.
  • Funds reported $6.42B of Rhythm Pharmaceuticals stock for Q1 2026, down 18% quarter-over-quarter.
  • 64 funds opened new Rhythm Pharmaceuticals positions in Q1 2026 and 51 closed out, a net change of +13 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $123M added.
  • The largest Rhythm Pharmaceuticals seller in Q1 2026 was NEA Management Company, an estimated $311M sold.

Based on aggregated 13F filings for Q1 2026.